Is AOD-9604 Safe? What the Evidence Says

What Is AOD-9604?

AOD-9604 is a synthetic peptide fragment derived from the C-terminal end of human growth hormone, specifically amino acids 176 to 191. Researchers at Monash University in Australia developed it in the 1990s with the goal of isolating the fat-metabolizing properties of growth hormone without triggering the insulin-like effects associated with the full molecule. The name stands for Anti-Obesity Drug 9604.

The peptide works, at least in animal models, by stimulating lipolysis (the breakdown of fat) and inhibiting lipogenesis (the formation of new fat). Studies in obese mice published in the late 1990s showed meaningful reductions in body fat. Those animal findings were promising enough that the compound moved into human trials under the pharmaceutical company Metabolic Pharmaceuticals.

It is worth being clear about what AOD-9604 is not. It is not a growth hormone secretagogue, it does not meaningfully raise IGF-1 levels in the studies conducted so far, and it is not the same compound as full-sequence growth hormone or any approved growth hormone product. The distinction matters when evaluating what safety data actually applies to it.

What Did Human Trials Actually Find?

AOD-9604 went through Phase 1, Phase 2, and at least one Phase 3 clinical trial. The Phase 2 trials, conducted in the early 2000s and involving several hundred overweight and obese adults, tested oral formulations over periods ranging from 12 to 24 weeks. A 2001 publication in the American Journal of Clinical Nutrition reported on a 12-week, placebo-controlled trial of 300 obese adults. Participants receiving AOD-9604 showed modest reductions in body weight compared to placebo, and the compound was described as well-tolerated, with adverse events similar in frequency to the placebo group.

The Phase 3 trial, which enrolled over 500 participants, did not demonstrate statistically significant weight loss over placebo at the primary endpoint. Metabolic Pharmaceuticals halted further development for obesity after those results. The safety signals from these trials were not alarming, but the trials were not designed to detect rare adverse events, and none followed participants beyond 24 weeks.

One important limitation: most of the human trials used oral delivery. Much of the current interest in AOD-9604 involves subcutaneous injection, which is a different route of administration. The pharmacokinetics differ, and the safety profile established in oral trials does not automatically transfer to injected forms. No large published human trial has evaluated injected AOD-9604 safety specifically.

The U.S. Food and Drug Administration granted AOD-9604 GRAS (Generally Recognized as Safe) status as a food ingredient in 2014, based on the oral trial data. That designation applies narrowly to oral use as a food additive and does not constitute approval as a drug, does not cover injectable forms, and does not mean the compound is approved to treat any condition.

Documented Side Effects From Published Studies

Across the published human trials, the most commonly reported adverse events were mild and transient. These included headache, nausea, and injection-site reactions in studies that used subcutaneous delivery in earlier phases. The frequency of these events was generally comparable to placebo groups, which is a meaningful data point, though the trials were not large enough or long enough to rule out less common effects.

No serious cardiovascular events, liver toxicity signals, or hormonal disruptions were attributed to AOD-9604 in the published trial record. Researchers specifically monitored IGF-1 levels given the compound's structural relationship to growth hormone, and the trials did not find significant IGF-1 elevation. That is relevant because elevated IGF-1 is associated with certain cancer risks in other contexts.

Animal studies, including rodent work published in journals like Endocrinology, explored higher doses and longer durations than the human trials. Those studies did not flag major organ toxicity at doses relevant to the human trials. However, animal-to-human translation in peptide research is imperfect, and rodent safety data should not be read as a guarantee of human safety.

• Headache: reported in some trial participants, generally mild
• Nausea: noted in early-phase studies, typically transient
• Injection-site reactions: redness or discomfort at the injection site in subcutaneous delivery studies
• No significant IGF-1 elevation documented in published human trials
• No serious adverse events attributed to the compound in published trial data

Who Should Be Especially Cautious?

The human trial data excluded several populations entirely, which means there is no published safety information for them. Pregnant and breastfeeding people were not included in the trials. Children and adolescents were not studied. People with active cancer or a history of hormone-sensitive cancers were excluded, a standard precaution given the compound's structural link to growth hormone. Anyone in these groups has no trial data to draw on at all.

People with diabetes or insulin resistance should be aware that AOD-9604 was specifically designed to avoid insulin-related effects, and the trials did not show significant glucose disruption. Still, the trials were not long enough to evaluate chronic metabolic effects, and anyone managing blood sugar with medication should discuss any new compound with their prescribing physician before anything else.

People with kidney or liver conditions face a general gap in the data. The trials did not specifically enroll or analyze participants with impaired organ function, so clearance and metabolite behavior in those populations is not well characterized in the published literature.

Anyone considering AOD-9604 through a compounding pharmacy or research chemical supplier is working outside the regulated drug approval system. Purity, sterility, and accurate concentration are not guaranteed by any federal oversight body for these products. That is a safety variable entirely separate from the compound's pharmacology.

The Regulatory Picture and What It Means for Safety

AOD-9604 does not have FDA approval as a drug in any form. The GRAS designation from 2014 covers oral use as a food ingredient, a narrow category that does not authorize medical use or injectable administration. Compounded versions of AOD-9604 exist in the U.S. market, but compounded drugs occupy a different regulatory space than FDA-approved drugs and are not subject to the same pre-market safety and efficacy review.

In 2015, the FDA placed AOD-9604 on a list of bulk drug substances that may not be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. That action reflects the agency's position that the compound does not meet the criteria for compounding use, which is a meaningful regulatory signal even if it does not constitute a formal safety ban.

The practical consequence for anyone researching this compound is that the safety data available comes from trials conducted under a specific pharmaceutical development program that ended over a decade ago. No ongoing large-scale human safety monitoring exists. The gap between what was studied and what is currently circulating in the research chemical market is wide, and that gap is a safety concern in itself.